Short answer: Yes. On December 15, 2025 the Judicial Panel on Multidistrict Litigation created MDL 3163 for lawsuits claiming GLP-1 drugs caused NAION (non-arteritic anterior ischemic optic neuropathy), a sudden loss of blood flow to the optic nerve that can cause permanent vision loss. 278 cases were pending on November 2, 2026.
The panel kept vision claims separate from the stomach-injury MDL but sent them to the same judge, Karen S. Marston, so the two can be coordinated. In June 2025 the European Medicines Agency’s safety committee recommended listing NAION as a very rare side effect of semaglutide (Ozempic, Wegovy, Rybelsus), meaning it may affect up to 1 in 10,000 people. That is a regulator’s label decision, not a court finding that the drug caused any one person’s vision loss.
- Cases usually involve a NAION diagnosis by an eye doctor after starting a GLP-1 drug.
- Records that matter: the prescription history, the date vision changed, and the ophthalmology exam.
- No NAION settlement or verdict exists.
If this happened to you, a free, confidential case review can check whether your timeline fits.
SourcesMDL 3163 transfer orderJPML, 15 Dec 2025EMA PRAC June 2025European Medicines AgencyJPML report2 Nov 2026


